STOCKHOLDER EQUITY (Details) - USD ($) |
1 Months Ended | 3 Months Ended | 4 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 28, 2020 |
Jul. 14, 2020 |
Jan. 09, 2013 |
Feb. 16, 2021 |
Jun. 30, 2021 |
Mar. 31, 2021 |
Jun. 30, 2020 |
Mar. 31, 2020 |
Dec. 31, 2020 |
Jun. 30, 2021 |
Jun. 30, 2020 |
Dec. 31, 2020 |
Dec. 31, 2019 |
|
| STOCKHOLDER EQUITY (Details) [Line Items] | |||||||||||||
| Preferred Stock, Dividend Payment Terms | declared a dividend of one preferred share purchase right for each outstanding share of BioSig’s common stock to stockholders of record on July 27, 2020, and one right will be issued for each new share of common stock issued thereafter. Each right will initially trade with common stock, and will allow its holder to purchase from BioSig one one-thousandth of a share of Series F Junior Participating Preferred stock | ||||||||||||
| Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | |||||||
| Preferred Stock, Redemption Price Per Share (in Dollars per share) | $ 50.00 | ||||||||||||
| Preferred Stock, Voting Rights | In the event that a person or group acquires beneficial ownership of 12% or more of BioSig’s then outstanding common stock, subject to certain exceptions, each right would entitle its holder (other than such person or members of such group) to purchase additional shares of BioSig’s common stock having a market value of two times the exercise price of the right. In addition, at any time after a person or group acquires 12% or more of BioSig’s outstanding common stock (unless such person or group acquires 50% or more), the Board may exchange one share of BioSig’s common stock for each outstanding right (other than rights owned by such person or group, which would have become void). The Rights Plan could make it more difficult for a third party to acquire control of BioSig or a large block of our common stock without the approval of our board of directors. The rights will expire on July 13, 2021, unless terminated earlier by our board of directors | ||||||||||||
| Preferred Stock, Shares Authorized | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | ||||||||
| Common Stock, Shares, Issued | 32,205,479 | 30,764,792 | 32,205,479 | 30,764,792 | |||||||||
| Stock Issued During Period, Shares, Issued for Services | 443,640 | 658,868 | |||||||||||
| Stock Issued During Period, Value, Issued for Services (in Dollars) | $ 140,000 | $ 1,777,000 | $ 108,000 | $ 1,917,000 | $ 2,658,224 | ||||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 9,375 | ||||||||||||
| Proceeds from Stock Options Exercised (in Dollars) | $ 28,000 | $ 2,229,000 | |||||||||||
| Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture | 77,084 | ||||||||||||
| At the Market Offering (in Dollars) | $ 45,000,000.0 | $ 116,000,000.0 | |||||||||||
| Commission Rate | 3.00% | ||||||||||||
| Stock Issued During Period, Shares, New Issues | 251,720 | ||||||||||||
| Stock Issued During Period, Value, New Issues (in Dollars) | $ 1,300,135 | $ 16,162,000 | $ 9,052,000 | ||||||||||
| Payments of Stock Issuance Costs (in Dollars) | $ 40,365 | ||||||||||||
| Exercise of Options [Member] | |||||||||||||
| STOCKHOLDER EQUITY (Details) [Line Items] | |||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 9,375 | ||||||||||||
| Proceeds from Stock Options Exercised (in Dollars) | $ 27,750 | ||||||||||||
| Series A Preferred Stock [Member] | |||||||||||||
| STOCKHOLDER EQUITY (Details) [Line Items] | |||||||||||||
| Preferred Stock, Shares Authorized | 200 | 200 | 200 | 200 | |||||||||
| Series B Preferred Stock [Member] | |||||||||||||
| STOCKHOLDER EQUITY (Details) [Line Items] | |||||||||||||
| Preferred Stock, Shares Authorized | 600 | 600 | 600 | 600 | |||||||||
| Series C Preferred Stock [Member] | |||||||||||||
| STOCKHOLDER EQUITY (Details) [Line Items] | |||||||||||||
| Preferred Stock, Dividend Payment Terms | payable quarterly | ||||||||||||
| Preferred Stock, Voting Rights | The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder. | ||||||||||||
| Preferred Stock, Shares Authorized | 4,200 | 4,200 | 4,200 | 4,200 | |||||||||
| Series D Preferred Stock [Member] | |||||||||||||
| STOCKHOLDER EQUITY (Details) [Line Items] | |||||||||||||
| Preferred Stock, Shares Authorized | 1,400 | 1,400 | 1,400 | 1,400 | |||||||||
| Series E Preferred Stock [Member] | |||||||||||||
| STOCKHOLDER EQUITY (Details) [Line Items] | |||||||||||||
| Preferred Stock, Shares Authorized | 1,000 | 1,000 | 1,000 | 1,000 | |||||||||
| Series F Preferred Stock [Member] | |||||||||||||
| STOCKHOLDER EQUITY (Details) [Line Items] | |||||||||||||
| Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ 0.001 | ||||||||||||
| Preferred Stock, Shares Authorized | 200,000,000 | 200,000 | 200,000 | 200,000 | 200,000 | ||||||||